Program
SHR-4597
A development code. Also written as “SHR4597”.
Its studies are mostly in Asthma, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 2since Apr 16, 2025 | Apr 23, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2024First study: phase 1 study in Healthy SubjectsFirst studyNCT06385964 · 62 enrolled · China
- Apr 16, 2025Phase 2 study in AsthmaNCT06940700 · 60 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06940700Asthma · China | 2 | Not yet recruiting | Oct 2025 | 60 |
| NCT06385964Healthy Subjects · China | 1 | Completed | Feb 19, 2025 | 62 |
How it is read
Names in the registry
- “SHR-4597”, 1 entry
- “SHR4597”, 1 entry
Codes read as this program: SHR4597.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.